Investor
Access Portal

Restricted to accredited investors

This portal contains confidential information intended solely for accredited investors with a pre-existing relationship with DDS Founders Fund. Securities offered pursuant to Regulation D, Rule 506(b).

Confidential Investor Brief — June 2026

The
Defragmentation
Thesis

Prahsys is rebuilding the financial and clinical infrastructure of dentistry — one layer at a time. From 20+ disconnected tools to a single intelligent platform.

$500B
Dental Payments Market
3
Platform Layers
70%
Practices Vulnerable to Fraud
$4M
Remaining in Current Raise
Company Overview

You can't defragment
what you can't measure

The average dental practice runs on 20+ disconnected tools. None share a payment processor. None share a patient record. Every tool is an island — and dentists are paying for the chaos. 70% of practices are currently vulnerable to financial fraud and embezzlement as a result.

Prahsys built the financial layer first. Money touches every part of a dental practice. By owning the financial ledger — the single source of truth for every dollar — every layer built on top has context no standalone tool can match.

The strategy is modelled on Toast in restaurants: give solutions that grow customer revenue, and more revenue means more payments processed through Prahsys. Each new layer deepens the relationship and widens the moat.

The Problem
20+ software tools per practice. 6 separate merchant accounts minimum. 70% fraud vulnerability. 0 dominant fintech players in dental. The market is wide open.
The Foundation
Prahsys owns the financial ledger. One unified merchant account, one source of truth for every dollar. Gateway + Processor + Payops collapsed into a single API-native integration.
The Moat
Three layers — Payments, Patients, PrognosiX — that no competitor can replicate without owning all three. Each practice adds data that makes every layer smarter.
Why Now
Payments infrastructure is live. Agentic AI makes the patient layer possible at a cost that wasn't viable three years ago. No dominant player exists. Network effects are starting.
Investment Opportunity

Current Round
$4M remaining

Round Terms
Total Capital Target $10M
Previously Raised $4M
Current Raise $6M
Committed to Date $2M
Remaining $4M
Structure SAFE
Post-Money Cap $50M
$2M committed $4M remaining
Use of Funds — 18 Months
Product Dev / Eng
44.9%
Sales
15.3%
Legal / FDA / Compliance
12.2%
Management
7.0%
Finance & Investor Relations
5.4%
Sales Commissions
6.4%
Customer Support
3.8%
Marketing
3.7%
Investment Thesis

Why the proof points
compound over time

Customer proof point
70% fraud and embezzlement rate in dental
What it means for investors
The problem is structural, widespread, and largely unaddressed. PulseAI's centralised oversight addresses the root cause — fragmented systems with no unified financial visibility — rather than the symptom.
Customer proof point
$8,000 average saving per practice
What it means for investors
Hard, quantifiable, immediate ROI. Shortens payback periods, reduces churn risk, and makes the customer acquisition math straightforward.
Customer proof point
DSO channel
What it means for investors
One DSO relationship equals dozens of practices at a fraction of the unit economics of direct sales. The enterprise multiplier changes the growth model materially.
Customer proof point
Toast model strategy
What it means for investors
A proven playbook from an adjacent market that reached a multi-billion dollar outcome. Give customers tools that grow their revenue — the payments volume follows. The flywheel is understood and the analogy is credible.
Customer proof point
PrognosiX and ADA 2026 guidance
What it means for investors
Regulatory mandate creates pull. The ADA defined the problem in January 2026 — PrognosiX is the solution the market is now being pushed toward. Regulatory tailwind is more durable than sales-driven adoption.
Customer proof point
AI agent PMS strategy
What it means for investors
Capital-light path to broad PMS compatibility without a multi-year API development programme. Removes the largest technical bottleneck in healthcare payments and creates a structural advantage over integration-dependent competitors.
Customer proof point
PrognosiX free until 2027
What it means for investors
Clinical adoption volume before commercial scaling. Practices that adopt PrognosiX are warm PulseAI prospects — the free launch is a customer acquisition strategy as much as a product strategy.
Customer proof point
DentiMax integration live
What it means for investors
Proof of execution. The first live PMS integration validates the technical approach and the go-to-market model before the AI agent strategy scales it. Evidence of delivery, not just direction.
Milestones & Traction

Foundation to
commercial scale

2024 — Foundation
Founded
Prahsys Inc. established
Dental AI-first business formed. Q2 2024.
Infrastructure
Payment facilitator rails built
Payments module infrastructure complete. Q3 2024.
Capital
$3.95M raised
$450K pre-seed + $3.5M seed. Team and product build begins. Q4 2024.
2025 — Build & Launch
Acquisition
PrognosiX acquired
AI DICOM segmentation platform. Q2 2025.
Pilot
DentiMax pilot complete
First PMS channel partner validated. 2,500+ practices. Q4 2025.
Product
Ledger Base accounting system
Payments reconciliation layer complete. Q4 2025.
Partnership
DentTracks channel signed
Second PMS channel partner. 300 practices. Q4 2025.
Regulatory
FDA pre-submission meeting
PrognosiX 510(k) pre-submission completed. December 2025.
2026 — Scale
Launch
Payments product released
General availability for PMS partners. Q1 2026.
Team
John Soderberg joins as CRO
Sales-led GTM motion launched. 28 years dental industry experience. Q1 2026.
Team
Kevin Kyser joins as CFO
Financial leadership and discipline secured. Q2 2026.
IP
PrognosiX patent pending
AI intellectual property protected. Q2 2026.
Pipeline
22 partnership pipeline
4 finalising, 18 in active discussions. May 2026.
Partner Pipeline

Signed and pending
partnerships

Partner
Status
Detail
Scaled Value
DentiMax
Signed
Traditional API integration, first and proof of concept. 2,500+ practices.
$18M ARR
DentTracks
Signed
Approximately 300 practices.
$2.2M ARR
Prosperident
Signed
Leading dental fraud and embezzlement audit firm. Referring practices and advising on product development.
Referral
Alphaeon Credit
LOI Signed
Patient financing data integration into PulseAI dashboard. Mutual referral arrangement.
Integration
Cloud Dentistry
Pending
Payments partnership. 36,000 practices.
$259M ARR
Voxel Dental
Pending
$85M revenue business. PrognosiX at 65 CBCT installations/month plus 200 service calls. Est. 3,900 installations over 5 years.
$18.6M ARR
SotaCloud
Pending
PrognosiX AI partnership. 2,000 practices.
$7.6M ARR
AccessEndo
Pending
PrognosiX AI partnership. 500 practices.
$1.9M ARR

Scaled values represent potential annual revenue at full customer adoption within signed/pending partner networks. Not guaranteed.

Product

One platform.
Three layers.

Layer 3 — Clinical AI
PrognosiX
FDA 510(k) Submitted
Patent Pending
Layer 2 — Intelligence
Prahsys Patients
Agentic AI
Patient Lifecycle
Layer 1 — Foundation
Prahsys Payments
Live Now
Revenue Generating
No competitor owns all three layers. Prahsys does.
Live — Revenue Generating
Prahsys Payments
The financial foundation. A single merchant account replacing 6+ for every payment channel a dental practice needs.
  • Unified merchant account — card present, CNP, text-to-pay
  • Single financial ledger — every dollar in one place
  • API-native — gateway + processor + payops collapsed
  • Real-time fraud and embezzlement detection
  • 106 basis points net per dollar processed
  • $0 hidden fees. 5 min setup. Free terminal.
Initial Release
Prahsys Patients
Agentic AI built on top of the financial ledger. Because Prahsys owns the financial data, these AI agents know more than any standalone patient tool ever could.
  • AI fills cancelled slots from ranked waitlists automatically
  • Personalised patient recall based on payment and clinical history
  • In-house membership plans built into the financial layer
  • Plain-language AI tasks — "send recall to every patient 6 months overdue"
  • Unified inbox — SMS, email, portal all tied to patient context
  • Lab cases and referral workflow automation
FDA 510(k) Submitted
PrognosiX AI
Clinical AI that closes the loop. A diagnosis in PrognosiX triggers a treatment plan, which connects to a payment plan, which triggers automated patient follow-up. No manual handoff.
  • First true 3D X-ray AI to market
  • Patent pending — trained on proprietary Prahsys data
  • Pixel-level CBCT imaging analysis with colour mapping
  • Connects clinical finding directly to financial outcome
  • $399/month per practice at launch
  • ~70% EBITDA margins on AI revenue

PrognosiX is an investigational device under development and is not approved for clinical diagnosis or treatment decisions. Subject to FDA 510(k) clearance.

Leadership & Board

Operators who've
lived the problem

Grey Bonin
Founder & CEO
Grey Bonin
15+ years in healthcare. Serial entrepreneur who previously scaled a startup to multimillion-dollar revenue in three years. B.S. Biomedical Sciences, Texas A&M.
Ethan Bonin
Co-Founder & CTO
Ethan Bonin
10 years in fintech and medical enterprise software. Chief architect of Prahsys payments technology and PrognosiX AI. Google Cloud certified. Colorado School of Mines.
John Soderberg
Chief Revenue Officer
John Soderberg
28 years driving revenue across dental industry. Former Global Director of Enterprise Sales, Carestream Dental. 17 years at Patterson Dental including 9 as Northwest Region President.
Board & Advisors
Charlie Wright
Executive Chairman
Charlie Wright
Fortune 500 leadership. AI, cybersecurity, risk management and corporate governance. CPA, CIA, CISA. Oklahoma State + Tulsa MBA.
Kevin Kyser
Chief Financial Officer
Kevin Kyser
40+ years guiding companies through growth, restructuring and M&A. Former public company CFO. Deep financial expertise across healthcare and technology.
Richard Carson
Board Member & CLO
Richard Carson
30+ years as general counsel. FDA medical device, HIPAA, PCI-DSS, securities law. J.D. University of Oklahoma.
Tiberius Vadan
Board Member
Tiberius Vadan
30+ years at IBM, KPMG, Alvarez & Marsal. Multi-billion dollar strategic transformation experience.
Documents

Investor
materials

↓
Pitch Deck
Investor Deck v8
Full company presentation. May 2026. Covers market, product, team, financials and investment opportunity.
Download PDF →
↓
Investor Brief
Momentum Brief
Company timeline from founding to commercial launch. Milestones, partnerships and pipeline summary. May 2026.
Download PDF →
↓
One Pager
Company Summary
Single page overview including financials, team, market size, competitive positioning and investment terms.
Download PDF →
↓
One Pager
Full Company Brief
In-depth overview covering financials through 2030, product roadmap, leadership team and investment terms.
Download PDF →
⬡
Data Room
Public Diligence Room
Full public diligence room including key personnel, legal counsel and venture capital relationships.
View Data Room →
Product Demo
PrognosiX AI Demo
AI imaging enhancement on live CBCT dental scans.
Investor Updates

Monthly
reporting cadence

First Update June 2026 — Monthly investor update coming. Updates will cover KPIs, partnership progress, product milestones and material events.